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Abstract
Background: Diarrheal disease, which affects 1 in 4 people in the United Kingdom annually, is the most common cause of
outbreaks in community and health care settings. Traditional surveillance methods tend to detect point-source outbreaks of diarrhea
and vomiting; they are less effective at identifying low-level and intermittent food supply contamination. Furthermore, it can take
up to 9 weeks for infections to be confirmed, reducing slow-burn outbreak recognition, potentially impacting hundreds or thousands
of people over wide geographical areas. There is a need to address fundamental problems in traditional diarrheal disease surveillance
because of underreporting and subsequent unconfirmed infection by patients and general practitioners (GPs); varying submission
practices and selective testing of samples in laboratories; limitations in traditional microbiological diagnostics, meaning that the
timeliness of sample testing and etiology of most cases remains unknown; and poorly integrated human and animal surveillance
systems, meaning that identification of zoonoses is delayed or missed.
Objective: This study aims to detect anomalous patterns in the incidence of gastrointestinal disease in the (human) community;
to target sampling; to test traditional diagnostic methods against rapid, modern, and sensitive molecular and genomic microbiology
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methods that identify and characterize responsible pathogens rapidly and more completely; and to determine the cost-effectiveness
of rapid, modern, sensitive molecular and genomic microbiology methods.
Methods: Syndromic surveillance will be used to aid identification of anomalous patterns in microbiological events based on
temporal associations, demographic similarities among patients and animals, and changes in trends in acute gastroenteritis cases
using a point process statistical model. Stool samples will be obtained from patients’ consulting GPs, to improve the timeliness
of cluster detection and characterize the pathogens responsible, allowing health protection professionals to investigate and control
outbreaks quickly, limiting their size and impact. The cost-effectiveness of the proposed system will be examined using formal
cost-utility analysis to inform decisions on national implementation.
Results: The project commenced on April 1, 2013. Favorable approval was obtained from the Research Ethics Committee on
June 15, 2015, and the first patient was recruited on October 13, 2015, with 1407 patients recruited and samples processed using
traditional laboratory techniques as of March 2017.
Conclusions: The overall aim of this study is to create a new One Health paradigm for detecting and investigating diarrhea and
vomiting in the community in near-real time, shifting from passive human surveillance and management of laboratory-confirmed
infection toward an integrated, interdisciplinary enhanced surveillance system including management of people with symptoms.
International Registered Report Identifier (IRRID): DERR1-10.2196/13941
(JMIR Res Protoc 2019;8(9):e13941)  doi: 10.2196/13941
KEYWORDS
gastrointestinal diseases; syndromic surveillance; microbiology; diarrhea; vomiting
Introduction
Background
Diarrheal disease, affecting 1 in 4 people in the United Kingdom
annually [1], is the most common cause of infectious disease
outbreaks in community and health care settings. Traditional
surveillance methods tend to detect point-source outbreaks of
diarrhea and vomiting; however, they are less effective at
identifying low-level and intermittent contamination of the food
supply, unless the organism is very rare. Furthermore, it may
take up to 9 weeks for infections to be confirmed by a reference
laboratory, reducing recognition of slow-burn outbreaks that
can affect hundreds or thousands of people over a wide
geographical area.
There is a need to address fundamental problems inherent in
traditional surveillance for diarrheal disease. First, surveillance
depends on the examination of stool samples obtained from
symptomatic patients attending their general practitioner (GP).
The submission practices and selective testing of samples in
laboratories can vary and potentially fragment current
laboratory-based surveillance systems. Furthermore, as fewer
people present in person to their GP, laboratory-based systems
have become less sensitive; the hidden burden of disease has
increased [1]. Second, limitations of traditional microbiological
diagnostic methods mean that the etiology of diarrhea in most
cases remains unknown. Third, diagnostics are conducted in a
hierarchical manner (local detection, confirmation, and typing
centrally at national reference laboratories), which can take
several days and can be delayed during busy periods such as
when an outbreak investigation is underway. Finally, although
many diarrheal diseases are zoonotic, human and animal
surveillance systems are poorly integrated, meaning that
identification of zoonotic events, including emergence of new
or antibiotic-resistant strains, is delayed or missed altogether.
Overall Study Aim
The overall aim of this study is to create a new One Health
paradigm for detecting and investigating diarrhea and vomiting
in the community in near-real time, shifting from passive human
surveillance for gastrointestinal (GI) illness and management
of laboratory-confirmed infection toward an integrated,
interdisciplinary enhanced surveillance system including
management of people with symptoms.
Contribution to the Field
The comparison of the use of syndromic surveillance for cluster
detection and targeted sampling within the community with the
use of traditional surveillance will provide a series of
improvements to the surveillance of GI disease. We hypothesize
that enhanced GI surveillance will allow the following:
• Faster identification of outbreaks of GI disease
• More accurate characterization of the hidden burden of
disease (underreporting of episodes of illness in which
patients do not visit GPs in person). This will result in an
observed increase in the incidence of outbreaks
• Identification of a greater number of routes for transmission
of pathogens that cause GI illness.
The integration of human and animal syndromic surveillance
systems and the use of modern microbiological methods within
this project are hypothesized to facilitate (1) faster detection of
zoonotic transmission events; (2) earlier identification of a
greater spectrum of disease-transmitting pathogens, reducing
the diagnostic gap for GI disease; and (3) a reduction in the
numbers of false-positive and false-negative stool samples.
There will be differences in the costs and benefits of using
improved surveillance methods to detect outbreaks of GI disease
earlier compared with using traditional surveillance methods.
Potentially, these differences could be in parameters relating to
host-pathogen interactions; rate parameters that define the
transition of patients among relevant states (eg, susceptible,
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diseased, and symptomatic and/or infectious); test
characteristics, defined by sensitivity, specificity, and positive
and negative predictive values; costs (associated with screening,
patients’ use of National Health Service [NHS] community,
primary and secondary care services, treatments, and other
investigations); health outcomes (defined by health state
utilities); personal social services; days absent from work or
education; and other potential cost impacts.
Overall Objectives of the Research Program
The overall objectives of this research program are to (1)
develop and implement new sampling and microbiological
testing algorithms, including strategies for pathogen discovery
and evolutionary biology; (2) run the new system alongside the
existing system to assess its performance against a set of
outcome-based indicators including time to detection of event,
compliance with sampling among people with symptoms,
numbers of false-positive and false-negative stool samples, and
diagnostic yield; and (3) determine the costs and benefits of the
new system.
Methods
Setting
The setting is the North West area of England (population 7.1
million).
Case Recruitment and Informed Consent
A total of 4 data streams will feed in real time into the new
surveillance program. They are NHS 111 telephone triage data
on symptoms of vomiting and diarrhea (a real-time syndromic
surveillance system operated by Public Health England [PHE]),
data from the Small Animal Veterinary Surveillance Network
[2], and Salmonella data from the Animal and Plant Health
Agency (APHA).
The fourth data stream will be derived from general practices
in the Royal College of General Practitioners’ Research and
Surveillance Centre National Monitoring Network (RCGP RSC
NMN) [3]. Members of the public with symptoms of acute
gastroenteritis including a case definition of vomiting and
diarrhea who seek health advice from general practices in the
RCGP RSC NMN will be invited to submit a stool sample for
microbiological examination. Their consent for this procedure
will be sought because normal care would not necessarily entail
stool sampling for most patients unless their symptoms were
severe or had persisted for a long time. It is possible that most
patients will be recruited as part of a telephone consultation
with a member of their primary health care team (physician
assessment by telephone). The primary health care team will
arrange for the patient to receive through the post an invitation
letter, an information sheet about the study, a consent form, a
stool sampling kit with a reply-paid envelope, and a short Public
Health Acute Gastroenteritis questionnaire (which is part of
routine public health practice) with a reply-paid envelope.
Patients who present at a general practice in the RCGP RSC
NMN will receive these items in person. Patients who consent
to take part and provide a stool sample will be recruited into
the study. Consent statements agreed to in the study consent
form include acknowledgment that taking part in the study is
voluntary and that consenting patients can leave at any time.
Figures 1 and 2 describe the study recruitment procedure,
processes, and data flows using flow diagrams.
We aim to recruit 6000 participants. This will allow us to detect
the period (annual) prevalence of symptomatic GI infection in
the community of 20% ± 1%.
Sample Processing
On receipt at 1 of the 3 diagnostic laboratories taking part (Royal
Liverpool and Broadgreen University Hospitals NHS Trust,
Central Manchester University Hospitals NHS Foundation Trust,
or Lancashire Teaching Hospitals NHS Foundation Trust), the
stool sample will be divided into 2 parts. One part of the sample
will be processed according to routine clinical practice at each
of the 3 laboratories. The other half will be processed with a
rapid first-line diagnostic screen, using a molecular multiplex
real-time polymerase chain reaction (PCR) assay (a
commercially available CE-marked kit [Luminex xTAG
Gastrointestinal Pathogen Panel, xTAG GPP] [4]), which
incorporates most of the major community GI pathogens
relevant to the United Kingdom. This will be complemented by
tests for Enteroaggregative Escherichia coli and Sapovirus,
which have been incorporated into the xTAG GPP assay, using
assays already developed for PHE’s Olympics Response [5].
Downstream from the rapid xTAG GPP diagnosis, an algorithm
for testing stool samples from presumed outbreaks using
next-generation sequencing technologies will allow for
molecular characterization of known pathogens. Where a
pathogen has not been identified (likely in 60% of samples),
samples from clinically severe outbreaks will be fast-tracked
and characterized using a relatively low-throughput platform
for combined RNA/DNA viromes and bacterial metagenomes.
If they are from less clinically urgent cases, they will be
sequenced at reduced cost on a high-throughput platform.
If a patient does not wish to take part in the study but does
submit a stool sample, this case will be processed according to
routine clinical practice.
All results will be reported to the patient’s GP. Results from
the Luminex assays will be issued as an interim report through
Telepath, which is the routine electronic reporting system
between diagnostic laboratories and general practice, and the
results of the routine clinical practice assays will be issued as
a final report through Telepath. In each laboratory, an
experienced consultant medical microbiologist, who is a
coinvestigator on the grant with research time costed into it,
will be available to discuss any discrepant results with the
patient’s GP. The most likely scenario is that a stool sample
that provides negative results using traditional methods will
provide positive results using the xTAG GPP. This is to be
expected because the xTAG GPP, which is a multiplexed PCR,
will detect the presence of pathogen DNA/RNA in stool even
if an organism has died-off in the sample during transit to the
laboratory.
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Figure 1. Patient recruitment flow diagram and study processes for the INTEGRATE project. ASAP: as soon as possible; xTAG GPP: Luminex xTAG
Gastrointestinal Pathogen Panel.
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Figure 2. Post patient recruitment data flow for the INTEGRATE project. AEGISS: Ascertainment and Enhancement of Gastrointestinal Surveillance
and Statistics; AGE: Public Health Acute Gastroenteritis; HES: Hospital Episode Statistics; HSCIC: Health and Social Care Information Centre; NHS:
National Health Service; PHE: Public Health England; RCGP: Royal College of General Practitioners; UoL: University of Liverpool.
Public Health Acute Gastroenteritis Questionnaires
Public Health Acute Gastroenteritis (AGE) questionnaires will
be returned to PHE's health protection teams using reply-paid
envelopes. These questionnaires contain the routine follow-up
information that is collected and collated by the PHE to assist
outbreak detection or investigation. In addition, these
questionnaires will contain questions on quality of life during
the acute illness. Quality of life will be measured using the
EuroQol-5D-3L [6], which is the gold standard tool. This gives
snapshots of quality of life at points in time. At this time point
(time point 1), we will capture the quality of life during the
acute illness.
Resource Use and Costs
Resource use and costs will be assessed from several different
perspectives, described below, including the public sector and
patients.
Public Sector, Including National Health Service and
Social Services
Consistent with National Institute for Health and Care
Excellence’s (NICE) methods for the development of public
health guidance, we will adopt a public sector costing
perspective. Although productivity costs are not routinely
included in analyses, we will collect the data for consideration
in sensitivity analysis. Unit costs will be derived from standard
sources such as the Personal Social Services Research Unit
Costs of Health and Social Care, the British National Formulary
for drug costs, and NHS reference costs. The costs of laboratory
and public health services will be obtained from PHE.
Patients
Patients who indicate in their consent form that they are willing
to be contacted about a Patient Experience Survey (PES) will
receive a questionnaire that seeks information about resource
use 2 weeks after returning their stool sample pot. Most patients
will have recovered fully 2 weeks later, and therefore, a
complete picture of the costs they incurred because of their
illness should be available. The short resource use questionnaires
will capture details about the use of health care services,
personal social services, days absent from work or school, and
other potential costs. Quality of life, using EuroQol-5D-3L, will
be assessed during the acute episode (time point 1) and at 2
weeks post recovery (time point 2). It will be used to calculate
quality-adjusted life-years (QALYs).
Hospital Episode Statistics
Patients’ use of secondary care services will be assessed by
accessing Hospital Episode Statistics data sourced from NHS
Digital. This will require a bespoke download, matching patients
who have consented according to their NHS number, name, and
date of birth, following a standard operating procedure to ensure
patient anonymity and data protection.
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Costs of Technology
These will include setup costs, including capital costs, the
marginal costs of delivering the service, and the cost
implications for patients using the NHS services. These costs
will be obtained from Luminex and from time and motion
studies conducted at participating microbiology laboratories.
Patient Experience Survey
The purpose of this survey is to explore service users’ and,
where relevant, their caregivers’ perceptions and experiences
of accessing the INTEGRATE service. Questions contained
within the PES were developed from themes identified from
the extant literature and include (1) motivations for accessing
health care in relation to diarrhea; (2) predisposing or enabling
motivations for accessing a given health care service; (3)
experience and perceptions including the acceptability of
self-stool sampling; and (4) dimensions of patient satisfaction,
including, for example, communication and clarity of
information.
Members of the public eligible to participate in the survey will
be either a patient (aged ≥16 years) who has recently suffered
from diarrhea and provided a stool sample, or a person who has
parental, guardian, or caregiver responsibility for, and who will
act as a proxy on behalf of, a patient who has recently suffered
from diarrhea and provided a stool sample.
There was no upper age limit for sampling patients. However,
where the patient is a minor (aged <16 years), the parent,
guardian, or caregiver will be invited to respond on their behalf
(as a proxy). We estimate approximately 5000 members of the
public will be eligible to take part in the survey within a time
frame of 15 months. During this period, all eligible participants
will be consecutively recruited to participate in the survey as a
means to achieving maximum variation in clinical and
sociodemographic characteristics and to facilitate comparison
across key purposive sampling criteria [7]. Participants will be
invited to complete the questionnaire 2 weeks after returning
their stool self-sample pot, allowing a 3-week recall period from
the date of contact with the NHS.
Survey Distribution
When a member of the public contacts a collaborating GP, they
will receive information in their study pack about the patient
experience survey. If they express an interest in finding out
more about this survey, they will be asked to identify a preferred
contact route by either receiving a self-completion questionnaire
through the post or accessing a Web-based self-completion
questionnaire.
If prospective participants choose to receive this information
through the post, they will be sent a public survey information
pack containing an introductory letter, an information sheet
explaining the aims of the study and the processes involved in
participating in the survey, a copy of the self-completion
questionnaire, and a prepaid return envelope addressed to the
Project Office at the University of Liverpool. If prospective
participants prefer to access these details online, they will
receive an email. The email will include an electronic link to a
secure, Web-enabled system containing a study introduction
page. If interested, prospective participants can then access 2
further links. The first link will open an information page, which
will outline the aims of the study and processes involved in
participating in the online survey. The second link will enable
prospective participants to access and complete the electronic
version of the self-completion questionnaire (through the PHE
Select Survey facility [8]).
Participants will be given 2 weeks to complete and return/submit
their questionnaire. Nonresponders will be prompted (through
their preferred route) with 1 follow-up reminder. These will
include, as appropriate, a follow-up letter containing a further
copy of the questionnaire and a prepaid return envelope or a
follow-up email with an electronic link to the online
questionnaire. The use of reminders is generally endorsed in
texts on survey methods [9].
Summary of Outcome Measures
The outcome measures to be quantified within the research
project are summarized in Table 1.
Plan of Analyses
Anomaly Detection
The underlying statistical model for human case incidence will
be a spatiotemporal Cox process [10] in which the rate of calls
at location x and time t is modeled as ρ(x,t)=λ(x)μ(t)R(x,t),
where λ(x) and μ(t) describe the normal patterns of variation in
the spatial and temporal dimensions, respectively, of the call
rate, thereby taking account of the geographical distribution of
the user population, seasonal variation in disease risk, and
reporting artifacts such as day-of-the-week effects. The term
R(x,t) is a stochastic process with expected value 1 and
represents unforeseen, spatially and temporally localized
variations in the underlying disease risk.
Model parameters will be estimated by likelihood-based methods
and fed into algorithms that update the predictive distribution
of the unexpected component R(x,t) automatically on receipt of
each day’s incident call data. Results will be posted overnight
in the form of maps showing localities, if any, where the data
indicate a high probability that the current value of R(x,t)
exceeds a specified threshold.
System Performance
The performance of the new surveillance system compared with
routine sampling will be assessed by analyzing the
outcome-based indicators and comparing time with detection,
decision to act, and the size of outbreaks described using both
traditional and new diagnostic systems (range, mean, and median
number of cases), outbreak settings, modes of transmission
identified, and vehicles identified. Each critical time point along
the diagnostic and detection pathway from symptom onset to
diagnosis and detection of a cluster or outbreak will be
examined.
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Table 1. Resource use and costs outcome measures to be quantified within the research program.
How to measureOutcome measures
Resource use and costs outcome measures
Resource use questionnaire (PESa) to patientsUse of health care services
Resource use questionnaire (PES) to patientsUse of personal social services
Resource use questionnaire (PES) to patientsDays absent from work or education
Resource use questionnaire (PES) to patientsOther potential cost impacts
Hospital Episode Statistics from NHSb DigitalUse of secondary care services
Interviews with Luminex (new technology) and time and motion studies at microbiology
laboratories (existing technology)
Costs of technology
EQ-5D-3Lc questionnaire administered at 2 time points: time point 1, during the acute
illness; and time point 2, 2 weeks after return of the Acute Gastroenteritis Questionnaire
Health outcome
System outcome measuresd
Laboratory records, date of AEGISSe anomaly detection, date that Consultants in Com-
municable Disease Control initiate an investigation
Time to detection of event
Laboratory records (number of samples requested) and GPf records (number of samples
submitted)
Compliance with sampling among people with symp-
toms
Laboratory recordsTime to detection of a positive result
Laboratory recordsNumbers of false-positive and false-negative stool
samples
Calculated from laboratory records using the formula: Σ true positives/Σ test outcome
positives (ie, true positives + false positives)
Positive predictive value
Laboratory records: percentage of negative samples using either systemDiagnostic gap
Outbreak investigation reports: range, mean, and median numbers of casesSize of outbreaks detected
aPES: Patient Experience Survey.
bNHS: National Health Service.
cEQ-5D-3L: EuroQol-5D-3L descriptive system.
dThese will be captured for traditional methods and new diagnostic technology.
eAEGISS: Ascertainment and Enhancement of Gastrointestinal Surveillance and Statistics.
fGP: general practitioner.
Economic Modeling
The model structure will be based on a decision analysis in
which the alternative options will be specified according to
treatment pathways and strategies for public health intervention.
The impact and scale of outbreaks will be modeled using
agent-based models in which hypothetical cohorts are subject
to an instantaneous rate of infection, which varies depending
on the proportion of the population who are infected. This
approach has several advantages over the traditional health
economic models, which are restrictive in their predictive
capabilities, and scenario testing. The model will be
parameterized with point estimates and associated variances,
derived from a purposive review of the published literature,
from routinely collected data from PHE (both historical and
contemporary), and from data generated during the research.
These will include parameters relating to host-pathogen
interactions; rate parameters that define the transition of patients
among relevant states (eg, susceptible, diseased, and
symptomatic and/or infectious); test characteristics, defined by
sensitivity, specificity, and positive and negative predictive
values; costs (associated with screening, patients’ use of NHS
community, primary and secondary care services, treatments,
and other investigations); and health outcomes (defined by
health state utilities based on UK tariff scores assigned to each
model state and mortality estimates).
Calculating and Judging Cost-Effectiveness
Expected costs and benefits will be estimated to calculate
incremental cost-utility ratios (costs per QALY gained) for a
range of scenarios, specified by infection type, clinical course,
and public health response. Estimates of the incremental
cost-effectiveness ratios (ICERs) will be compared with the
£20,000 to £30,000 per QALY threshold of cost-effectiveness
set by NICE, and a range of one-way sensitivity analyses will
be conducted to assess the robustness of the analysis. These
will be presented as a Tornado plot. Multivariate sensitivity
analyses will be applied where interaction effects are suspected.
The joint uncertainty in all parameter estimates will be
propagated through the model by use of probabilistic sensitivity
analysis and construction of cost-effectiveness acceptability
curves that present the probability of clinical strategies being
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cost-effective, conditional on the chosen threshold for
cost-effectiveness (representing the marginal value of health).
Scenario analyses representing, for example, changes in service
configuration will be conducted to estimate a range of ICERs
for different circumstances.
Ethics
For the human case data, ethics permissions and approvals have
been obtained from the following:
• National Research Ethics Service, REC reference:
15/NW/0233
• NHS Health Research Authority Confidential Advisory
Group (CAG), CAG reference: 15/CAG/0131
• The Information Governance Toolkit, Department of Health
and Social Care hosted by the Health and Social Care
Information Centre (now NHS Digital), UoL reference:
8HN20, Lancaster University reference:
EE133831-HAM-EAOPOCR
• NHS Research Management and Governance Committees,
IRAS number: 173789
• University of Liverpool Ethics Sub-Committees, reference:
UoL001111
• Honorary NHS contracts, research passports, and letters of
access have been obtained for research staff working on
the project as necessary.
Results
The project commenced on April 1, 2013. Favorable approval
was obtained from the Research Ethics Committee on June 15,
2015, and the first patient was recruited on October 13, 2015,
with 1407 patients recruited and samples processed using
traditional laboratory techniques as of March 2017.
Discussion
This study investigates whether modern microbiological
methods can be used to improve surveillance for GI disease
while also examining the costs and limitations associated with
the enhanced system. It compares the results obtained using
traditional laboratory techniques with those obtained using
modern sensitive molecular and genomic microbiology
techniques. The strength of the study is the collaboration
between lead public health partners and researchers in this field.
However, there are a number of challenges in this study. For
example, the plans for work are based on the assumption that
implementation of the surveillance streams and their providers
will continue in their current form for at least the period of study
recruitment. Ethical permissions are granted under this proviso,
but as with the provision of all health services, changes can
occur rapidly. If there are changes to the study protocol, then
these must be reflected in amendments to the ethics agreements,
and the research governance including confidentiality
agreements required for this to happen can take a significant
amount of time to go through the review process, delaying the
progression of data collection. Another challenge is that of
recruiting a sufficiently large number of patients for analysis,
to allow reasonable comparison of the results of the traditional
and modern microbiological testing. This is particularly true,
given that GPs often do not encourage patients to provide a
stool sample unless they have had clinical GI symptoms for an
extended period or unless they are in a high-risk group such as
those who are young, old, or immunocompromised.
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